



an Open Access Journal by MDPI

Lung Cancer: Tumor Progression and Target Therapy

Guest Editors:

Prof. Dr. Alberto Ricci

Department of Clinical and
Molecular Medicine, Sapienza
University of Rome, Rome, Italy

Prof. Dr. Rita Mancini

Dipartimento di Medicina Clinica
e Molecolare, II Facoltà di
Medicina e Chirurgia, Policlinico
S. Andrea, Università "La
Sapienza", 00189 Roma, Italy

Deadline for manuscript
submissions:

closed (30 April 2023)

Message from the Guest Editors

The aim of the present Special Issue will be focused on well-designed studies and research able to improve our knowledge of lung cancer, our understanding of the mechanisms underlying tumor initiation, propagation, and progression, and ameliorate the influence or change direction in lung cancer diagnosis and therapy. As a consequence, these works may give the basis for novel therapeutic approaches, early or more specific diagnostic procedures. Not only clinical but also basic science research is encouraged. In addition, works aiming to translate basic knowledge into the clinic, such as treatment and prevention, diagnosis, and novel therapeutic modalities, will be also considered. Articles in this Special Issue may include reviews and researcher papers. The issue comprehensively covers many areas of interest and could be of interest to a broad range of readers, including physicians, scientists, students, and pharmaceutical companies.

Prof. Dr. Alberto Ricci

Prof. Dr. Rita Mancini

Guest Editors



mdpi.com/si/60213

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI